| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥640.8B | ¥647.7B | -1.1% |
| Operating Income | ¥85.7B | ¥102.5B | -16.4% |
| Ordinary Income | ¥72.9B | ¥106.6B | -31.7% |
| Net Income | ¥54.8B | ¥82.0B | -32.5% |
| ROE | 5.7% | 9.1% | - |
FY2026 Q3 consolidated results show revenue of 64.1B yen (YoY -1.1%), operating income of 8.6B yen (YoY -16.4%), ordinary income of 7.3B yen (YoY -31.7%), and net income attributable to owners of 5.5B yen (YoY -32.5%). While top-line performance remained relatively stable, profit margins compressed significantly due to foreign exchange losses of 1.3B yen and deteriorating working capital efficiency. Operating margin declined to 13.4% from prior year levels, with net profit margin at 8.7%. The company maintains full-year guidance of 90.0B yen in revenue, 12.0B yen in operating income, and 9.5B yen in net income, implying recovery in Q4 contingent upon working capital normalization and forex headwind mitigation.
[Profitability] ROE of 5.8% reflects compressed profitability compared to industry dynamics, with net profit margin at 8.7% (down from prior year) and operating margin at 13.4%. The DuPont decomposition reveals net profit margin compression as the primary ROE driver, with total asset turnover at 0.385x and financial leverage at 1.73x. Tax burden ratio stands at 0.763 and interest burden at 0.850, indicating material non-operating expenses. Operating income to revenue ratio of 13.4% remains in acceptable range for pharmaceutical operations but represents deterioration from prior periods. [Cash Quality] Cash and deposits total 51.7B yen with short-term debt coverage of 1.02x against short-term borrowings of 36.5B yen. Working capital shows stress with inventory increasing 36.6% YoY to 11.7B yen and accounts receivable expanding, resulting in days sales outstanding of 167 days and inventory turnover of 244 days. [Investment Efficiency] Total asset turnover of 0.385x indicates moderate capital efficiency. Inventory turnover days at 244 days and receivables turnover at 167 days point to working capital cycle elongation. Interest coverage ratio of 23.6x provides adequate debt service cushion despite profit compression. [Financial Health] Equity ratio of 57.8% reflects solid capitalization with total equity of 96.0B yen against total assets of 166.2B yen. Current ratio of 133.4% and quick ratio of 113.2% indicate near-term liquidity adequacy. Debt-to-equity ratio of 0.43x remains conservative, though debt composition heavily weighted toward short-term borrowings at 36.5B yen versus long-term debt of 4.4B yen creates refinancing considerations. Short-term liabilities represent 89.3% of total liabilities at 62.6B yen.
Cash and deposits increased 2.8B yen YoY to 51.7B yen, though profit generation declined significantly during the period. Working capital deterioration is evident with inventory expanding 3.1B yen YoY to 11.7B yen and accounts receivable increasing 2.4B yen to 29.3B yen, collectively absorbing substantial operating cash. The inventory buildup of 36.6% YoY significantly exceeds revenue growth trajectory and represents a material cash consumption factor. Trade payables increased modestly to 12.7B yen, providing limited offset to working capital outflows. Long-term borrowings decreased from 6.9B yen to 4.4B yen, while short-term borrowings constitute the primary funding source at 36.5B yen, indicating a strategic shift toward shorter-duration financing. Total interest-bearing debt of 40.9B yen against equity of 96.0B yen yields debt-to-capital of 29.8%. Cash coverage of short-term liabilities at 1.02x provides limited cushion for operational volatility. The company declared interim dividend of 23 yen per share with year-end dividend guidance of 24 yen per share, representing approximately 43.3% of earnings at current profit levels. Working capital efficiency metrics show cash conversion cycle elongation driven by both inventory accumulation and receivables extension, warranting operational focus on collection and inventory optimization to restore cash generation capacity.
Ordinary income of 7.3B yen versus operating income of 8.6B yen reflects negative non-operating net contribution of approximately 1.3B yen, primarily driven by foreign exchange losses of 1.3B yen recorded during the period. This represents a material deterioration from prior year when forex impact was less pronounced. Interest expense of 0.4B yen remains manageable with interest coverage ratio of 23.6x demonstrating adequate debt service capability. The divergence between operating income decline of 16.4% and ordinary income decline of 31.7% highlights the outsized impact of non-operating factors, particularly forex translation effects. Non-operating expenses represent approximately 2.0% of revenue, concentrated in currency fluctuations rather than core operational inefficiencies. While operating cash flow data is not disclosed for the quarterly period, balance sheet analysis suggests earnings quality concerns stemming from working capital expansion that likely pressured cash generation below reported accrual earnings. Inventory growth of 36.6% substantially exceeding revenue trajectory and receivables accumulation both indicate potential cash conversion challenges. Comprehensive income of 8.5B yen for the nine-month period includes positive other comprehensive income contributions, partially offsetting profit decline. The recurring earnings base remains centered on operating performance from Ethical Drug and Consumer Healthcare segments contributing 7.9B yen and 5.2B yen in operating income respectively, though forex volatility introduces earnings variability that may persist depending on currency exposure management.
Foreign exchange volatility represents material earnings risk with 1.3B yen in forex losses recorded in Q3, equivalent to 1.8% of revenue. Currency exposure management and hedging effectiveness warrant monitoring as forex fluctuations directly impact ordinary income despite stable operating performance.
Working capital deterioration with inventory increasing 36.6% YoY to 11.7B yen and accounts receivable expanding creates dual risk of cash flow pressure and potential asset quality concerns. Inventory turnover extended to 244 days raises obsolescence risk in pharmaceutical products subject to shelf-life constraints, while receivables at 167 days DSO indicate collection cycle elongation.
Refinancing risk from debt maturity structure with short-term borrowings of 36.5B yen representing 89.3% of interest-bearing debt. Heavy reliance on short-term funding sources creates exposure to credit market conditions and interest rate movements, with limited cushion as cash coverage ratio stands at only 1.02x against short-term obligations.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin of 13.4% significantly outperforms pharmaceutical industry median of -218.2% (IQR: -628.8% to -14.9%), positioning the company in the upper performance tier. Net profit margin of 8.7% similarly exceeds industry median of -216.8%, reflecting sustainable profitability versus loss-making peer median. ROE of 5.8% substantially outperforms industry median of -35.8% (IQR: -91.4% to -6.1%), though remains below absolute performance benchmarks at 2025-Q3.
Financial Health: Equity ratio of 57.8% aligns closely with industry median of 67.8% (IQR: 62.1% to 79.1%), indicating comparable capital structure conservatism. Current ratio of 133.4% trails industry median of 662% materially, reflecting more normalized working capital positioning versus highly liquid pharmaceutical peers, though still adequate for operational needs.
Efficiency: Asset turnover of 0.385x substantially exceeds industry median of 0.17 (IQR: 0.05 to 0.24), demonstrating superior capital efficiency and revenue generation per asset base. Inventory turnover of 244 days compares favorably to industry median of 282 days, though recent inventory accumulation trends warrant continued monitoring. Receivables turnover of 167 days aligns with industry median of 152 days, indicating comparable collection cycle performance.
Growth: Revenue decline of 1.1% outperforms industry median contraction of 12.5% (IQR: -22.1% to -2.5%), demonstrating relative top-line resilience. The company maintains positive profit generation versus widespread industry losses, though profit growth momentum has decelerated.
(※ Industry: Pharmaceutical (13 companies), Comparison: 2025-Q3 fiscal periods, Source: Proprietary analysis)
Profit margin compression driven by operational and forex factors presents near-term earnings headwind requiring Q4 recovery execution. Operating income declined 16.4% while ordinary income fell 31.7%, with the incremental 15.3 percentage point decline attributable to 1.3B yen foreign exchange losses. The company's full-year guidance implies significant Q4 profit recovery with operating income reaching 12.0B yen annually versus 8.6B yen through Q3, requiring 3.4B yen in Q4 versus 8.6B yen in first nine months. This recovery assumption depends on forex stabilization and operating leverage improvement that may face execution risk given current trajectory.
Working capital cycle deterioration demands operational intervention with inventory and receivables jointly expanding 5.5B yen YoY. Inventory days extended to 244 days with 36.6% YoY growth substantially exceeding revenue trends, suggesting demand forecasting misalignment or product mix shifts requiring correction. Receivables at 167 days DSO indicate collection cycle elongation that pressures cash conversion. Combined working capital impact likely constrained operating cash flow below earnings levels, creating tension between reported profitability and cash generation that warrants resolution for dividend sustainability and growth investment capacity.
Short-term funding concentration creates refinancing exposure requiring strategic liability management. Short-term borrowings of 36.5B yen represent 89.3% of debt with cash coverage at 1.02x, limiting financial flexibility during operational volatility. While debt-to-equity of 0.43x remains conservative and interest coverage of 23.6x provides adequate cushion, the maturity profile concentration introduces refinancing risk particularly if working capital normalization delays or market conditions tighten. Strategic extension of debt duration would enhance financial stability and reduce rollover vulnerability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.